Sirolimus – An accompanying treatment for COVID-19 in elderly persons?!

Researchers globally combat the COVID-19 pandemia. Data generated suggest that COVID-19 is a major threat for elderly in regards to being more dangerous and more severe. Even when a successful vaccine for SARS-CoV-2 becomes available, an additional drug might be necessary in order to boost the immune response in vaccinated but weakened persons.

Rapamycin/Sirolimus is commonly used as an immunosuppressant. Rapamycin and other compounds of this class target the so called mTOR pathway (mechanistic Target of Rapamycin). Paradoxically, this compound also exerts immunostimulatory effects such as boosting T cell response in reaction to pathogen infection and vaccination. (Ferrer IR, Araki K, Ford ML. Paradoxical aspects of rapamycin immunobiology in transplantation. Am J Transplant. 2011; 11:654–59. https://doi.org/10.1111/j.1600-6143.2011.03473.x PMID:21446969).

This would be not the first time a physiological paradox is discovered in clinical medicine. We refer here to the administration of beta-blockers to heart failure patients. In order to proof the effectiveness of Rapamycin to specific age-associated diseases, substantial pre-clinical validations applications in human trials will be necessary.

Cfm Oskar Tropitzsch GmbH is working with Rapamycin for >20 years. We can provide R&D grade material as well as cGMP grade Rapamycin produced in Europe along with all required documents like CoA, SDS and an EDMF.

Cfm provides – as usual – cutting-edge compounds to make the world a more-healthy place.

Reach out to us for more information. michael.schaeffler@cfmot.de